Jacek Kwiecien

Dr. Jacek Kwiecien

Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Jacek KwiecienJacek Kwiecien
Jacek Kwiecien
WDWojciech Dabrowski
Wojciech Dabrowski
BDBeata Dąbrowska-Bouta
Beata Dąbrowska-Bouta
GSGrzegorz Sulkowski
Grzegorz Sulkowski
WOWendy Oakden
Wendy Oakden
ALAlexandra R. Lucas
Alexandra R. Lucas
The pathogenesis of spinal cord injury (SCI) remains poorly understood and treatment remains limited. Emerging evidence indicates that post-SCI inflammation is severe but the role of reactive astrogliosis not well understood given its implication in ongoing inflammation as damaging or neuroprotective. We have completed an extensive systematic study with MRI, histopathology, proteomics and ELISA analyses designed to further define the severe protracted and damaging inflammation after SCI in a rat model. We have identified 3 distinct phases of SCI: acute (first 2 days), inflammatory (starting day 3) and resolution (>3 months) in 16 weeks follow up. Actively phagocytizing, CD68+/CD163- macrophages infiltrate myelin-rich necrotic areas converting them into cavities of injury (COI) when deep in the spinal cord. Alternatively, superficial SCI areas are infiltrated by granulomatous tissue, or arachnoiditis where glial cells are obliterated. In the COI, CD68+/CD163- macrophage numbers reach a maximum in the first 4 weeks and then decline. Myelin phagocytosis is present at 16 weeks indicating ongoing inflammatory damage. The COI and arachnoiditis are defined by a wall of progressively hypertrophied astrocytes. MR imaging indicates persistent spinal cord edema that is linked to the severity of inflammation. Microhemorrhages in the spinal cord around the lesion are eliminated, presumably by reactive astrocytes within the first week post-injury. Acutely increased levels of TNF-alpha, IL-1beta, IFN-gamma and other pro-inflammatory cytokines, chemokines and proteases decrease and anti-inflammatory cytokines increase in later phases. In this study we elucidated a number of fundamental mechanisms in pathogenesis of SCI and have demonstrated a close association between progressive astrogliosis and reduction in the severity of inflammation.

19 September 2023 in Cell Reports Medicine
Verified
Journal Article
Open access
EDEric M. Desjardins
Eric M. Desjardins
JWJianhan Wu
Jianhan Wu
DLDeclan C.T. Lavoie
Declan C.T. Lavoie
EAElham Ahmadi
Elham Ahmadi
LTLogan K. Townsend
Logan K. Townsend
GSGregory R. Steinberg
Gregory R. Steinberg
Increased liver de novo lipogenesis (DNL) is a hallmark of nonalcoholic steatohepatitis (NASH). A key enzyme controlling DNL upregulated in NASH is ATP citrate lyase (ACLY). In mice, inhibition of ACLY reduces liver steatosis, ballooning, and fibrosis and inhibits activation of hepatic stellate cells. Glucagon-like peptide-1 receptor (GLP-1R) agonists lower body mass, insulin resistance, and steatosis without improving fibrosis. Here, we find that combining an inhibitor of liver ACLY, bempedoic acid, and the GLP-1R agonist liraglutide reduces liver steatosis, hepatocellular ballooning, and hepatic fibrosis in a mouse model of NASH. Liver RNA analyses revealed additive downregulation of pathways that are predictive of NASH resolution, reductions in the expression of prognostically significant genes compared with clinical NASH samples, and a predicted gene signature profile that supports fibrosis resolution. These findings support further investigation of this combinatorial therapy to treat obesity, insulin resistance, hypercholesterolemia, steatohepatitis, and fibrosis in people with NASH.

1 January 2016 in Neurologia i Neurochirurgia Polska
Verified
Journal Article
Closed access
Jacek KwiecienJacek Kwiecien
Jacek Kwiecien
BJBozena Jarosz
Bozena Jarosz
WOWendy Oakden
Wendy Oakden
MKMichal Klapec
Michal Klapec
GSGreg J. Stanisz
Greg J. Stanisz
WDWojciech Dabrowski
Wojciech Dabrowski
Current therapies to limit the neural tissue destruction following the spinal cord injury are not effective. Our recent studies indicate that the injury to the white matter of the spinal cord results in a severe inflammatory response where macrophages phagocytize damaged myelin and the fluid-filled cavity of injury extends in size with concurrent and irreversible destruction of the surrounding neural tissue over several months. We previously established that a high dose of 4mg/rat of dexamethasone administered for 1 week via subdural infusion remarkably lowers the numbers of infiltrating macrophages leaving large amounts of un-phagocytized myelin debris and therefore inhibits the severity of inflammation and related tissue destruction. But this dose was potently toxic to the rats. In the present study the lower doses of dexamethasone, 0.125-2.0mg, were administered via the subdural infusion for 2 weeks after an epidural balloon crush of the mid-thoracic spinal cord. The spinal cord cross-sections were analyzed histologically. Levels of dexamethasone used in the current study had no systemic toxic effect and limited phagocytosis of myelin debris by macrophages in the lesion cavity. The subdural infusion with 0.125-2.0mg dexamethasone over 2 week period did not eliminate the inflammatory process indicating the need for a longer period of infusion to do so. However, this treatment has probably lead to inhibition of the tissue destruction by the severe, prolonged inflammatory process.

23 April 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Jacek KwiecienJacek Kwiecien
Jacek Kwiecien
Liqiang ZhangLiqiang Zhang
Liqiang Zhang
Jordan YaronJordan Yaron
Jordan Yaron
LSLauren Schutz
Lauren Schutz
CKChristian J. Kwiecien-Delaney
Christian J. Kwiecien-Delaney
ALAlexandra Lucas
Alexandra Lucas
Spinal cord injury (SCI) results in massive secondary damage characterized by a prolonged inflammation with phagocytic macrophage invasion and tissue destruction. In prior work, sustained subdural infusion of anti-inflammatory compounds reduced neurological deficits and reduced pro-inflammatory cell invasion at the site of injury leading to improved outcomes. We hypothesized that implantation of a hydrogel loaded with an immune modulating biologic drug, Serp-1, for sustained delivery after crush-induced SCI would have an effective anti-inflammatory and neuroprotective effect. Rats with dorsal column SCI crush injury, implanted with physical chitosan-collagen hydrogels (CCH) had severe granulomatous infiltration at the site of the dorsal column injury, which accumulated excess edema at 28 days post-surgery. More pronounced neuroprotective changes were observed with high dose (100 µg/50 µL) Serp-1 CCH implanted rats, but not with low dose (10 µg/50 µL) Serp-1 CCH. Rats treated with Serp-1 CCH implants also had improved motor function up to 20 days with recovery of neurological deficits attributed to inhibition of inflammation-associated tissue damage. In contrast, prolonged low dose Serp-1 infusion with chitosan did not improve recovery. Intralesional implantation of hydrogel for sustained delivery of the Serp-1 immune modulating biologic offers a neuroprotective treatment of acute SCI.

3 October 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
AKAgata M. Kieliszek
Agata M. Kieliszek
DMDaniel Mobilio
Daniel Mobilio
DUDeepak Upreti
Deepak Upreti
DBDarin Bloemberg
Darin Bloemberg
LELaura Escudero
Laura Escudero
Sheila SinghSheila Singh
Sheila Singh
Purpose: Brain metastases (BM) are mainly treated palliatively with an expected survival of less than 12 months after diagnosis. In many solid tumors, the human neural stem cell marker glycoprotein CD133 is a marker of a tumor-initiating cell population that contributes to therapy resistance, relapse, and metastasis. Experimental Design: Here, we use a variant of our previously described CD133 binder to generate second-generation CD133-specific chimeric antigen receptor T cells (CAR-T) to demonstrate its specificity and efficacy against multiple patient-derived BM cell lines with variable CD133 antigen expression. Results: Using both lung- and colon-BM patient-derived xenograft models, we show that a CD133-targeting CAR-T cell therapy can evoke significant tumor reduction and survival advantage after a single dose, with complete remission observed in the colon-BM model. Conclusions: In summary, these data suggest that CD133 plays a critical role in fueling the growth of BM, and immunotherapeutic targeting of this cell population is a feasible strategy to control the outgrowth of BM tumors that are otherwise limited to palliative care. See related commentary by Sloan et al., p. 477

1 January 2015 in Folia Neuropathologica
Verified
Journal Article
Open access
Jacek KwiecienJacek Kwiecien
Jacek Kwiecien
BJBozena Jarosz
Bozena Jarosz
LULucia Machova Urdzikova
Lucia Machova Urdzikova
RRRadoslaw Rola
Radoslaw Rola
WDWojciech Dabrowski
Wojciech Dabrowski
Trauma in spinal cord injury often results in massive damage to the white matter and in damage to myelin that results in a severe phagocyte-rich infiltration apparently directed at removing immunologically toxic myelin debris. In the epidural balloon crush injury to the rat cranial thoracic...